18.08.2016 • NewsElaine BurridgeBayerMonsanto

Bayer Gets Limited Access to Monsanto’s Books

“In the coming weeks, CEO Werner Baumann will make a decision; namely whether...
“In the coming weeks, CEO Werner Baumann will make a decision; namely whether a friendly merger is still possible, or whether Bayer must choose an alternative path,” sources told Handelsblatt.

Monsanto is reported to have given Bayer limited access to its books after last month rejecting an improved takeover offer of $125/share, or around $65 billion. The parties have not yet signed a non-disclosure agreement, which would allow Bayer to conduct due diligence, but Monsanto is giving the German company a “limited drip” of information, according to Reuters news agency.

Sources said Bayer had no appetite to put a deal at risk by going hostile, although talks were “difficult.” An earlier news report in German business publication Handelsblatt, citing sources close to management, stated that Bayer officials were preparing to “turn directly to shareholders” to secure a deal if Monsanto insisted on a price which the Germans perceived as too risky. The US agrochemicals giant called the latest bid in July “financially inadequate.

 “In the coming weeks, CEO Werner Baumann will make a decision; namely whether a friendly merger is still possible, or whether Bayer must choose an alternative path,” sources told Handelsblatt.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Interview

Fostering Innovation and Collaboration
Specialty Chemicals Distributor IMCD’s Strategy

Fostering Innovation and Collaboration

Valerie Diele-Braun, CEO of IMCD, shares her vision for sustainability, global expansions, and strategic direction in an exclusive CHEManager International interview.

most read

Photo
27.03.2025 • News

J&J to Invest $55 Billion in US Operations

US healthcare giant Johnson & Johnson (J&J) has unveiled plans to invest over $55 billion in the US over the next four years. This significant investment marks a 25% increase compared to the previous four years, the company said.

Photo
19.03.2025 • NewsInnovation

Data-Driven Enzyme Immobilization

Inseit, based in Bern, develops biocatalysts for industrial setups using enzyme immobilization and biocomputation. Addressing biotech and sustainability challenges, Inseit was selected for Venture Leaders Biotech and won two Nucleate accelerator prizes.